Abstract

ESBLs are a group of plasmid-mediated, diverse, complex and rapidly evolving enzymes that pose a therapeutic challenge today in hospital- and community-acquired infections. Thirty-six years after the first report, diagnostic and therapeutic approaches for ESBLs are still the subject of controversy. Detection of these enzymes is recommended for epidemiological purposes and facilitates targeted therapy, necessary for antimicrobial stewardship. On the other hand, ESBLs are not confined to specific species, phenotypic detection methods have pitfalls, and concerns exist about the accuracy of antimicrobial susceptibility testing systems to rely on MIC values for cephalosporins and β-lactam combination agents. In this issue, we present a PRO/CON debate on ESBL testing for ceftriaxone-non-susceptible Enterobacterales.

Details

Title
Should ceftriaxone-resistant Enterobacterales be tested for ESBLs? A PRO/CON debate
Author
Villegas, Maria Virginia 1 ; Esparza, German 2 ; Reyes, Jinnethe 3 

 Grupo de resistencia antimicrobiana RAEH, Universidad El Bosque, Bogota, Colombia 
 Programa de proeficiencia en microbiología, PROASECAL SAS, Bogota, Colombia 
 Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogota, Colombia 
Publication year
2021
Publication date
Jun 2021
Publisher
Oxford University Press
e-ISSN
26321823
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3169983488
Copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.